Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies (ID3828)
National Institute for Health Research
· United Kingdom · £8.2M GBP
We use cookies to keep your session secure, remember your preferences, and analyse site traffic with Google Analytics.
By continuing to use GrantFunds you agree to our
Privacy Policy
and
Terms of Use.